The global bioburden testing market for bio-pharma contamination is approximately $10B, with over 350M tests run annually. LexaGene provides early detection for mycoplasma, aiding in validating product quality for biopharmaceutical manufacturers.
The MiQLab Bacterial & AMR test empowers veterinarians to make quick evidenced-based treatment decisions in-clinic.
LexaGene developed assays for pathogen detection and whether they possess drug resistant genes.
Single-use manufacturing has provided for a large degree of flexibility in terms of production volumes but have also brought about efficiencies in sterility control by reducing hands on cleaning and sterilization necessary for stainless steel.
Contamination control of bioprocessing cell lines is essential. The same environments that encourage desirable microbiological growth also encourage growth of undesirable contaminants including yeasts, molds, mycoplasma, bacteria, and viruses.
Improvements in qPCR testing are bringing point-of-care molecular diagnostics into practical use.
Making qPCR molecular diagnostics accessible at point-of-care changed how we detect and treat major infectious diseases.
Careful evaluation of a patient’s medical history, their clinical symptoms, and consultation of available diagnostic test results are essential components of implementing an effective antimicrobial stewardship program at a veterinary clinic.
On-site qPCR testing lets veterinarians make better treatment decisions faster than waiting on culture and sensitivity testing from a reference laboratory.
Overuse of antimicrobial agents in veterinary medicine contributes to the spread of resistance genes which undermine our ability to prevent or treat infectious disease.
Veterinary Antimicrobial Stewardship programs are critical to not only improve patient outcomes, but support global action against antimicrobial resistance.
Pandemic containment in the United States has proved ineffective due to a lack of preparation and deployment of modern pathogen-detection technologies. Improved point-of-care molecular diagnostics will save lives when the next pandemic emerges.